Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP8B1 | Q9UNU6 | 13/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765691 | 0.92 | CYP8B1 (0.35) | CYP8B1BTKDPP4PARP1PARP2 | |
| SCHEMBL31558512 | 0.91 | BTK (0.35) | CYP8B1BTKDPP4PARP1PARP2 | |
| SCHEMBL30765505 | 0.90 | GAA (0.34) | CYP8B1BTKDPP4HDAC6 | |
| SCHEMBL30766002 | 0.86 | USP2 (0.37) | BACE1PIK3CA | |
| SCHEMBL31558461 | 0.84 | BACE1 (0.43) | BACE1 | |
| SCHEMBL30766121 | 0.82 | MAPK1 (0.34) | CYP8B1BTKHDAC6 | |
| SCHEMBL30766008 | 0.80 | BACE1 (0.43) | BACE1PIK3CA | |
| SCHEMBL30765755 | 0.79 | BACE1 (0.37) | BACE1 | |
| SCHEMBL30765991 | 0.79 | ELANE (0.42) | — | |
| SCHEMBL30765957 | 0.79 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |